Arvinas, Inc. (ARVN) is a breakthrough biopharmaceutical company pioneering the development of targeted therapies for serious diseases. Its unique approach revolutionizes traditional methods of cancer treatment by focusing on protein degradation. This method has the potential to provide treatments for diseases that have been resistant to various therapies.
Arvinas was founded by Craig Crews, a professor at Yale University, in 2013 and is headquartered in New Haven, Connecticut, United States. The company derives its name from the Latin phrase "arvina", which translates to "the grease of sheep's wool". This represents a dedication to creating transformative solutions in the medical field, much as the grease of sheep's wool was used historically in myriad unique applications.
Highlighted by its Proteolysis-Targeting Chimeras (PROTAC) technology, Arvinas stands out in the pharmaceutical world. PROTAC harnesses the body's own natural process of protein degradation to eliminate disease-causing proteins, enabling innovations in treatment across a multitude of serious diseases, including cancer and neurodegenerative disorders.
Arvinas' lead products, ARV-110 and ARV-471, are proprietary investigational medications administered orally which are being evaluated for safety, tolerability, and durability of anti-tumor responses to potential treatments in phases of clinical trials. ARV-110 is an androgen receptor PROTAC protein degrader, being studied in men with metastatic castrate-resistant prostate cancer. ARV-471 is an estrogen receptor PROTAC protein degrader, undergoing clinical trials for patients with locally advanced or metastatic ER+/HER2- breast cancer.
Arvinas has also been actively contributing to research in neurodegenerative diseases. As of now, it's working extensively on a potential treatment for Huntington's disease and is also engaged in the development of a new class of small molecule drugs known as protein homeostasis regulators to treat serious neurological conditions, such as amyotropic lateral sclerosis (ALS) and frontal temporal dementia (FTD).
The company’s work has attracted the attention of large pharmaceuticals. Its high-profile partnerships include collaborations with Pfizer and Genentech, boosting its financial stability and R&D capabilities.
Arvinas, Inc.'s main distinction lies in its dedication to revolutionizing the approach to serious illnesses by introducing revolutionary methods based on protein degradation.
Stock exchange-wise, ARVN is traded publicly on Nasdaq and has had a strong growth trajectory. While any biotech venture carries inherit risk, Arvinas, Inc. demonstrates a promising future with its powerful technology platform and strategic partnerships. Overall, the company portrays a solid commitment towards treating deadly diseases with its innovative science and strategic collaborations. As the company continues its research and moves closer to FDA approval for its therapies, it will certainly be one to watch.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Arvinas Inc. reported significant progress in Q2 2026, including the FDA approval of its PROTAC degrader Vepanu, an out-licensing agreement with Rigel Pharmaceuticals, and a strategic decision to seek a partner for its KRAS G12D program. The company is now focusing on advancing its Phase 1 clinical programs for ARV393 (BCL6 degradation), ARV027 (polyglutamine repeat androgen receptors), and ARV102 (LRRK2 degradation). Arvinas ended the quarter with $567.9 million in cash, reported $249.7 million in total revenue, and expects its cash runway to last into the second half of 2028.
This article analyzes Arvinas Inc. (NASDAQ: ARVN) using AI models to provide technical signals for institutional trading. It highlights strong near and mid-term sentiment, potential resistance testing, and a weak long-term outlook. The report offers specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, emphasizing a significant risk-reward short setup.
GSA Capital Partners LLP recently purchased 142,214 shares of Arvinas, Inc. (NASDAQ:ARVN) valued at approximately $1.18 million, as disclosed in their latest 13F filing. Other institutional investors also adjusted their holdings, with several significantly increasing their stakes. Arvinas recently reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and several analysts have updated their ratings and price targets for the stock.
Evercore ISI Group has maintained an Outperform rating for Arvinas (ARVN) but lowered its price target from $19.00 to $14.00, reflecting a cautious outlook. Despite being significantly undervalued by GuruFocus's GF Value™ at $31.53 versus a current price of $8.95, the company faces financial challenges, high P/E ratios, and negative insider sentiment. Investors are advised to exercise caution and conduct thorough research due to the discrepancy between potential undervaluation and current financial indicators.
Citigroup has maintained a Buy rating for Arvinas (ARVN) but lowered its price target from $24.00 to $21.00, reflecting a 12.50% decrease. Despite this adjustment and concerns over profitability and insider selling, GuruFocus indicates ARVN is significantly undervalued with a GF Value™ of $31.53 against its current price of $9.01. The company shows strong growth potential but faces valuation and insider confidence challenges.
Morgan Stanley has lowered its price target for Arvinas (ARVN) to $10 from $11, while maintaining an Equalweight rating on the stock. This adjustment comes amidst other analyst activities concerning Arvinas, including Wedbush also adjusting its price target. The company, a clinical-stage biotechnology firm, continues to develop protein degradation therapies.